ZWS Stock Analysis: Zurn Elkay Water Solutions | NYSE
Pollution & Treatment Controls | NYSE, USA | Market Cap: 7.910m USD | 12M Return: 25.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 48.0M
EPS Trend: 98.5%
Qual. Beats: 10
Rev. Trend: 92.4%
Qual. Beats: 4
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Zurn Elkay Water Solutions Corporation designs, manufactures, and markets a broad portfolio of water management products serving institutional, commercial, waterworks, and residential end markets across the U.S., Canada, and internationally. Its offering spans water dispensing and filtration (Elkay, Halsey Taylor), water safety and control valves (Zurn, Wilkins), drainage and flow systems (Zurn, Green Turtle, Wade), sensor-operated flush valves and commercial faucets (Aquaflush, AquaSense, AquaVantage, AquaSpec, Hydro X Power), as well as sinks, restroom partitions, lockers, and hand dryers. The company reaches customers through independent sales representatives, plumbing wholesalers, and industry-specific distributors.
Headquartered in Milwaukee, Wisconsin, Zurn Elkay was founded in 1900 and was renamed from Zurn Water Solutions Corporation in July 2022. Within the broader Industrials sector, ZWS sits in the Building Products sub-industry, a category that includes manufacturers of components used in construction, plumbing, and water infrastructure - markets closely tied to non-residential construction activity, building retrofits, and regulatory standards governing safe drinking water and water conservation.
- Lead and Copper Rule revisions drive water safety product demand
- Non-residential construction backlog pressures institutional sales growth
- Copper and brass input costs compress gross margins amid pricing lag
| Net Income: 213.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 1.97 > 1.0 |
| NWC/Revenue: 33.22% < 20% (prev 28.76%; Δ 4.46% < -1%) |
| CFO/TA 0.13 > 3% & CFO 349.7m > Net Income 213.3m |
| Net Debt (331.9m) to EBITDA (391.6m): 0.85 < 3 |
| Current Ratio: 3.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (169.7m) vs 12m ago -1.46% < -2% |
| Gross Margin: 43.69% > 18% (prev 44.46%; Δ -0.77% > 0.5%) |
| Asset Turnover: 65.75% > 50% (prev 60.63%; Δ 5.12% > 0%) |
| Interest Coverage Ratio: 11.08 > 6 (EBIT TTM 304.6m / Interest Expense TTM 27.5m) |
| A: 0.22 (Total Current Assets 836.5m - Total Current Liabilities 258.5m) / Total Assets 2.68b |
| B: -0.42 (Retained Earnings -1.12b / Total Assets 2.68b) |
| C: 0.12 (EBIT TTM 304.6m / Avg Total Assets 2.65b) |
| D: 1.49 (Book Value of Equity 1.61b / Total Liabilities 1.08b) |
| Altman-Z'' = 2.39 = BBB |
| DSRI: 0.89 (Receivables 242.7m/247.7m, Revenue 1.74b/1.58b) |
| GMI: 1.02 (GM 44.46% / 43.69%) |
| AQI: 0.94 (AQ_t 0.63 / AQ_t-1 0.67) |
| SGI: 1.10 (Revenue 1.74b / 1.58b) |
| TATA: -0.05 (NI 213.3m - CFO 349.7m) / TA 2.68b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 47.35 with a total of 730,845 shares traded. Over the past week, the price has changed by -3.68%, over one month by +0.49%, over three months by -0.58% and over the past year by +25.17%.
Current recommended Stop Loss: 44.70 (which is 5.6% or 2.1 ATR below the current price).
Zurn Elkay Water Solutions has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold ZWS.
- StrongBuy: 3
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 56.5 | 19.3% |
P/E Trailing = 38.3821
P/E Forward = 25.9067
P/S = 4.5455
P/B = 5.1054
P/EG = 1.7249
Revenue TTM = 1.74b USD
EBIT TTM = 304.6m USD
EBITDA TTM = 391.6m USD
Long Term Debt = 497.6m USD (from longTermDebt, last quarter)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 605.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 53.2m
Net Debt = 331.9m USD (calculated: Debt 605.4m - CCE 273.5m)
Enterprise Value = 8.24b USD (7.91b + Debt 605.4m - CCE 273.5m)
Interest Coverage Ratio = 11.08 (Ebit TTM 304.6m / Interest Expense TTM 27.5m)
EV/FCF = 25.70x (Enterprise Value 8.24b / FCF TTM 320.7m)
FCF Yield = 3.89% (FCF TTM 320.7m / Enterprise Value 8.24b)
FCF Margin = 18.43% (FCF TTM 320.7m / Revenue TTM 1.74b)
Net Margin = 12.26% (Net Income TTM 213.3m / Revenue TTM 1.74b)
Gross Margin = 43.69% ((Revenue TTM 1.74b - Cost of Revenue TTM 979.9m) / Revenue TTM)
Gross Margin QoQ = 47.53% (prev 40.79%)
Tobins Q-Ratio = 3.07 (Enterprise Value 8.24b / Total Assets 2.68b)
Interest Expense / Debt = 4.54% (Interest Expense 27.5m / Debt 605.4m)
Taxrate = 24.11% (66.8m / 277.1m)
NOPAT = 231.2m (EBIT 304.6m * (1 - 24.11%))
Current Ratio = 3.24 (Total Current Assets 836.5m / Total Current Liabilities 258.5m)
Debt / Equity = 0.38 (Debt 605.4m / totalStockholderEquity, last quarter 1.61b)
Debt / EBITDA = 0.85 (Net Debt 331.9m / EBITDA 391.6m)
Debt / FCF = 1.03 (Net Debt 331.9m / FCF TTM 320.7m)
Total Stockholder Equity = 1.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.06% (Net Income 213.3m / Total Assets 2.68b)
RoE = 13.40% (Net Income TTM 213.3m / Total Stockholder Equity 1.59b)
RoCE = 14.58% (EBIT 304.6m / Capital Employed (Equity 1.59b + L.T.Debt 497.6m))
RoIC = 9.81% (NOPAT 231.2m / Invested Capital 2.36b)
WACC = 9.55% (E(7.91b)/V(8.52b) * Re(10.02%) + D(605.4m)/V(8.52b) * Rd(4.54%) * (1-Tc(0.24)))
Discount Rate = 10.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.67 | Cagr: -1.58%
[DCF] Terminal Value 74.18% ; FCFF base≈296.5m ; Y1≈339.8m ; Y5≈500.2m
[DCF] Fair Price = 35.23 (EV 6.21b - Net Debt 331.9m = Equity 5.88b / Shares 166.9m; r=9.55% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.54 | EPS CAGR: 26.54% | SUE: 3.54 | # QB: 10
Revenue Correlation: 92.42 | Revenue CAGR: 4.76% | SUE: 2.42 | # QB: 4
EPS current Quarter (2026-06-30): EPS=0.47 | Chg30d=-0.19% | Revisions=+77% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.48 | Chg30d=+0.29% | Revisions=+73% | Analysts=11
EPS current Year (2026-12-31): EPS=1.76 | Chg30d=+0.08% | Revisions=+77% | GrowthEPS=+15.7% | GrowthRev=+7.8%
EPS next Year (2027-12-31): EPS=1.93 | Chg30d=+0.27% | Revisions=+77% | GrowthEPS=+9.6% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: +93% (up=38, down=0)